HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

64Cu-SARTATE

for PET imaging of patients with neuroendocrine tumors

Also Known As:

(64)Cu-SARTATE; 64Cu-MeCOSar-Tyr3-octreotate

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - Octreotide: 5228
      - 64Cu-SARTATE: 1
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - Octreotide: 5228
      - 64Cu-SARTATE: 1

Experts

1.	Akhurst, Timothy A: 1 article (01/2019)
2.	Callahan, Jason: 1 article (01/2019)
3.	Donnelly, Paul S: 1 article (01/2019)
4.	Drummond, Elizabeth: 1 article (01/2019)
5.	Harris, Matthew: 1 article (01/2019)
6.	Hedt, Amos: 1 article (01/2019)
7.	Herschtal, Alan: 1 article (01/2019)
8.	Hicks, Lauren J: 1 article (01/2019)
9.	Hicks, Rodney J: 1 article (01/2019)
10.	Hofman, Michael S: 1 article (01/2019)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2019 - "Methods: In a prospective trial, 10 patients with known neuroendocrine neoplasia and positive for uptake on 68Ga-DOTA-octreotate (68Ga-DOTATATE) PET/CT underwent serial PET/CT imaging at 30 min, 1 h, 4 h, and 24 h after injection of 64Cu-SARTATE. " 01/01/2019 - "64Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy."
2.	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/01/2019 - "64Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy."

Related Drugs and Biologics

1.	Peptide Receptors (Peptide Receptor)
2.	Radioisotopes (Radionuclides)

Related Therapies and Procedures

1.	Therapeutics